Skip to main content
Midas Edge

Aptevo Therapeutics Inc.

For the period ended Dec 31, 2025. Filed Mar 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 26, 2026

APVO$1.08-4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits, Financial Statement Schedules

(a)

The following documents are filed as part of this report:

See Index to Consolidated Financial Statements at Item 8 herein.

Consolidated Financial Statement Schedules

All schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or notes thereto.

Exhibit Index

Exhibit Index

ExhibitNumber · Description · Form · Exhibit · Filing Date · File No. · FiledHerewith
2.1Contribution Agreement, dated July 29, 2016, by and among Emergent BioSolutions Inc., Aptevo Therapeutics Inc., Aptevo Research and Development LLC and Aptevo BioTherapeutics LLC8-K2.1August 2, 2016001-37746
+2.2Separation and Distribution Agreement, dated July 29, 2016, by and between Emergent BioSolutions Inc. and Aptevo Therapeutics Inc.8-K2.2August 2, 2016001-37746
†+2.3LLC Purchase Agreement, dated as of August 31, 2017, by and among Aptevo BioTherapeutics LLC, Aptevo Therapeutics Inc., Venus Bio Therapeutics Sub LLC, and Saol International Limited.10-Q2.1November 13, 2017001-37746
+2.4LLC Purchase Agreement by and among Aptevo Therapeutics Inc. and Medexus Pharma, Inc. dated February 28, 2020.8-K2.1March 2, 2020001-37746
3.1Amended and Restated Certificate of Incorporation of Aptevo Therapeutics Inc.8-K3.1August 2, 2016001-37746
3.2Amended and Restated By-laws of Aptevo Therapeutics Inc., as amended and restated on November 8, 2022.10-Q3.1November 10, 2022001-37746
3.3Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics Inc.8-K3.1March 27, 2020001-37746
3.4Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics, Inc.8-K3.1March 5, 2024001-37746
3.5Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics, Inc.8-K3.1December 3, 2024001-37746
3.6Certificate of Designation of Series A Junior Participating Preferred Stock of Aptevo Therapeutics Inc.8-K3.1November 9, 2020001-37746
3.7Amended and Restated Bylaws of Aptevo Therapeutics Inc.8-K3.1November 30, 2020001-37746
3.8Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics, Inc.8-K3.1May 23, 2025001-37746
3.9Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics, Inc.8-K3.1December 29, 2025001-37746
4.1Form of Common Stock Certificate104.1June 29, 2016001-37746
ExhibitNumber · Description · Form · Exhibit · Filing Date · File No. · FiledHerewith
4.2Registration Rights Agreement, dated as of August 1, 2016, by and among Aptevo Therapeutics Inc. and certain of its stockholders8-K4August 2, 2016001-37746
4.3Registration Rights Agreement, dated December 20, 2018, by and between Aptevo Therapeutics Inc. and Lincoln Park Capital Fund, LLC.8-K10.2December 24, 2018001-37746
4.4Rights Agreement, dated as of November 8, 2020, by and between Aptevo Therapeutics Inc. and Broadridge Corporate Issuer Solutions, Inc., as rights agent8-K4.1November 9, 2020001-37746
4.5Amendment No. 1 to Right Agreement, dated as of November 5, 2021, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent8-K4.1November 5, 2021001-37746
4.6Amendment No. 2 to Rights Agreement, dated as of November 4, 2022, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent.8-K4.1November 4, 2022001-37746
4.7Amendment No. 3 to Rights Agreement, dated as of November 2, 2023, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent8-K4.1November 2, 2023001-37746
4.8Amendment No. 4 to Rights Agreement, dated as of November 1, 2024, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent8-K4.1November 4, 2024001-37746
4.9Amendment No. 5 to Rights Agreement, dated as of October 30, 2025, between the Company and Broadridge Corporate Issuer Solutions, LLC, as Rights Agent8-K4.1October 30, 2025001-37746
4.10Description of Capital Stock of Aptevo Therapeutics4.5March 31, 2021001-37746
4.11Agreement to Terminate Registration Rights Agreement between the Company and Intervac L.L.C. and BioVac L.L.C.10-K4.1March 24, 2022001-37746
4.12Form of Series A Common Warrant, dated August 4, 20238-K4.1August 1, 2023001-37746
4.13Form of Series B Common Warrant, dated August 4, 20238-K4.2August 1, 2023001-37746
4.14Form of New Series A-1 Warrant8-K4.1November 9, 2023001-37746
4.15Form of New Series A-2 Warrant8-K4.2November 9, 2023001-37746
ExhibitNumberDescriptionFormExhibitFiling DateFile No.FiledHerewith
4.16Form of New Series B-1 Warrant8-K4.3November 9, 2023001-37746
4.17Form of New Series B-2 Warrant8-K4.4November 9, 2023001-37746
4.18Form of Common Warrant, dated April 15, 20248-K4.1April 15, 2024001-37746
4.19Form of Common Warrant, dated July 1, 20248-K4.1July 1, 2024001-37746
4.20Form of Common Warrant, dated September 18, 20248-K4.1September 18, 2024001-37746
4.21Form of Common Warrant, dated December 12, 20248-K4.1December 12, 2024001-37746
4.22Form of Common Warrant, dated April 4, 2025.8-K4.1April 4, 2025001-37746
4.23Form of Amended Common Warrant, dated April 4, 2025 (originally entered into on December 12, 2024), between the Company and certain warrant holders.8-K4.2April 4, 2025001-37746
4.24Common Warrant, dated June 20, 2025.8-K4.1June 20, 2025001-37746
10.1Transition Services Agreement, dated July 29, 2016, by and between Emergent BioSolutions Inc. and Aptevo Therapeutics Inc.8-K10.2August 2, 2016001-37746
10.2Tax Matters Agreement, dated July 29, 2016, by and between Emergent BioSolutions Inc. and Aptevo Therapeutics Inc.8-K10.3August 2, 2016001-37746
10.3Product License Agreement, dated July 29, 2016, by and between Emergent BioSolutions Inc. and Aptevo Therapeutics Inc.8-K10.8August 2, 2016001-37746
C 10.4Aptevo Therapeutics Inc. Amended and Restated 2016 Stock Incentive Plan.10-Q4.1August 10, 2017001-37746
C 10.5Aptevo Therapeutics Inc. Converted Equity Awards Incentive Plan8-K10.10August 2, 2016001-37746
C 10.6Aptevo Therapeutics Inc. Amended and Restated Senior Management Severance PlanX
C 10.7Form of Indemnity Agreement for directors and senior officers1010.9April 15, 2016001-37746
10.8Fourth and Battery Office Lease, dated as of April 28, 2003, by and between Emergent Product Development Seattle, LLC (as successor-in-interest to Trubion Pharmaceuticals, Inc. and Genecraft, Inc.) and Selig Real Estate Holdings Eight L.L.C. , or the Seattle Office Lease1010.12April 15, 2016001-37746
ExhibitNumber · Description · Form · Exhibit · Filing Date · File No. · FiledHerewith
10.9Seattle Office Lease Amendment, dated December 8, 20041010.13April 15, 2016001-37746
10.10Seattle Office Lease Amendment, dated February 1, 20061010.14April 15, 2016001-37746
10.11Seattle Office Lease Amendment, dated February 2, 20071010.15April 15, 2016001-37746
10.12Seattle Office Lease Amendment, dated June 7, 20101010.16April 15, 2016001-37746
10.13Seattle Office Lease Amendment, dated December 21, 20101010.17April 15, 2016001-37746
10.14Seattle Office Lease Amendment, dated July 17, 20121010.18April 15, 2016001-37746
10.15Seventh Amendment to Seattle Office Lease, dated December 5, 20141010.19April 15, 2016001-37746
†10.16License and Co-Development Agreement, dated as of August 19, 2014, by and between Emergent Product Development Seattle, LLC and MorphoSys AG, or the MorphoSys Collaboration Agreement1010.20June 29, 2016001-37746
†10.17First Amendment to MorphoSys Collaboration Agreement, dated June 19, 20151010.21April 15, 2016001-37746
†10.18Second Amendment to MorphoSys Collaboration Agreement, dated December 7, 20151010.22April 15, 2016001-37746
10.19Third Amendment to MorphoSys Collaboration Agreement, dated December 12, 20168-K10.1December 15, 2016001-37746
10.20Fourth Amendment MorphoSys Collaboration Agreement, dated June 19, 2017.1010.3August 10, 2017001-37746
10.21Equity Distribution Agreement, dated November 9, 2017, between Aptevo Therapeutics, Inc. and Piper Jaffray and Company LLC.8-K1.1November 9, 2017001-37746
10.22Collaboration and Option Agreement, dated as of July 20, 2017, by and between Aptevo Research and Development LLC, and Alligator Bioscience AB.10-Q10.2November 13, 2017001-37746
10.23Amendment No. 3 to Credit and Security Agreement, dated as of February 23, 2018, by and among Aptevo Therapeutics Inc. and certain of its subsidiaries and Midcap Financial Trust.10-K10.38March 13, 2018001-37746
10.24Aptevo Therapeutics Inc. 2018 Stock Incentive Plan.10-Q10.1August 9, 2018001-37746
10.25Aptevo Therapeutics Inc. Non-Statutory Stock Option Agreement.10-Q10.2August 9, 2018001-37746
10.26Purchase Agreement, dated December 20, 2018, by and between Aptevo Therapeutics Inc. and Lincoln Park Capital Fund, LLC.8-K10.1December 24, 2018001-37746
ExhibitNumber · Description · Form · Exhibit · Filing Date · File No. · FiledHerewith
10.27Eighth Amendment to Office Lease, dated as of March 19, 2019, by and between Aptevo Therapeutics Inc. and Selig Real Estate Holdings Eight L.L.C.8-K10.1March 22, 2019001-37746
10.28Ninth Amendment to Office Lease, dated May 26, 2022, by and between Aptevo Therapeutics Inc. and Selig Real Estate Holdings Eight L.L.C.8-K10.3August 11, 2022001-37746
10.29Amendment to LLC Purchase Agreement, dated as of August 31, 2017, by and among Aptevo BioTherapeutics LLC, Aptevo Therapeutics Inc., Venus Bio Therapeutics Sub LLC, and Saol International Limited.10-Q10.1August 9, 2019001-37746
10.30Collaboration and License Agreement, dated as of December 19, 2005, by and among Wyeth Pharmaceuticals and Trubion Pharmaceuticals, Inc.10-Q10.1August 14, 2020001-37746
10.31Amendment No. 1 to the Collaboration and License Agreement dated as of December 19, 2005 (the “Agreement”) by and between Trubion Pharmaceuticals, Inc. (“Trubion”) and Wyeth, acting through its Wyeth Pharmaceuticals Division (“Wyeth”).10-Q10.2August 14, 2020001-37746
10.32Amendment No. 2 to the Collaboration and License Agreement dated as of December 19, 2005 (as previously amended, the “Agreement”) by and between Trubion Pharmaceuticals, Inc. (“Trubion”) and Wyeth LLC (formerly known as Wyeth), acting through its Wyeth Pharmaceuticals Division (“Wyeth”).10-Q10.3August 14, 2020001-37746
10.33Amendment No. 3 to the Collaboration and License Agreement dated as of December 19, 2005 (as previously amended, the “Agreement”) by and between Emergent Product Development Seattle, LLC (successor to Trubion Pharmaceuticals, Inc. (“Trubion”)) (“EPDS”) and Wyeth LLC (formerly known as Wyeth), acting through its Wyeth Pharmaceuticals Division (“Wyeth”).8-K10.4August 14, 2020001-37746
10.34Amendment No. 4 to the Collaboration and License Agreement dated as of December 19, 2005 (as previously amended, the “Agreement”) by and between Emergent Product Development Seattle, LLC (successor to Trubion Pharmaceuticals, Inc. (“Trubion”)) and Wyeth LLC (formerly known as Wyeth), acting through its Wyeth Pharmaceuticals Division (“Wyeth”).10-Q10.5August 14, 2020001-37746
10.35Credit and Security Agreement, dated as of August 5, 2020, by and among Aptevo Therapeutics Inc., and MidCap Financial Trust.10-Q10.1November 10, 2019001-37746
ExhibitNumber · Description · Form · Exhibit · Filing Date · File No. · FiledHerewith
10.36Equity Distribution Agreement, dated December 14, 2020, between Aptevo Therapeutics Inc. and Piper Sandler & Co.8-K1.1December 14, 2020001-37746
10.37Royalty Purchase Agreement by and among Aptevo Therapeutics Inc. and Healthcare Royalty Partners IV, LP. dated as of March 30, 2021.10-Q10.1May 11, 2021001-37746
10.38Amendment to Royalty Purchase Agreement dated June 7, 2022.8-K10.1August 11, 2022001-37746
10.39First Amendment to Credit and Security Agreement dated March 30, 2021.10-Q10.2May 11, 2021001-37746
10.40Limited consent and Second Amendment to Credit and Security Agreement dated June 7, 2022.8-K10.2August 11, 2022001-37746
10.41Third Amendment to Credit and Security Agreement dated August 30, 2022.10-Q10.2November 10, 2022001-37746
10.42Executive Transition Services Agreement.10-Q10.3November 12, 2021001-37746
10.43Amendment to Executive Transition Services Agreement.10-Q10.4November 12, 2021001-37746
10.44Purchase Agreement, dated February 16, 2022, by and between the Company and Lincoln Park.8-K10.1February 17, 2022001-37746
10.45Registration Rights Agreement, dated February 16, 2022, by and between the Company and Lincoln Park.8-K10.2February 17, 2022001-37746
10.46Payment Interest Purchase Agreement by and between Aptevo Therapeutics Inc. and XOMA (US) LLC, dated March 29, 202310-Q10.1May 5, 2023001-37746
10.47Placement Agent Agreement, dated August 1, 2023, between the Company and A.G.P./Alliance Global Partners10-Q10.4August 10, 2023001-37746
10.48Securities Purchase Agreement, dated August 1, 2023, between the Company and the purchasers party thereto.10-Q10.5August 10, 2023001-37746
10.49Form of Warrant Inducement Agreement, by and between the Company and each Holder8-K10.1November 9, 2023001-37746
10.50Financial Advisory Agreement, dated as of November 9, 2023, between A.G.P./Alliance Global Partners and the Company8-K10.2November 9, 2023001-37746
10.51Securities Purchase Agreement, dated April 10, 2024, between the Company and the purchasers party thereto.8-K10.2April 15, 2024001-37746
10.52Securities Purchase Agreement, dated June 28, 2024, between the Company and the purchasers party thereto.8-K10.2July 1, 2024001-37746
ExhibitNumberDescriptionFormExhibitFiling DateFile No.FiledHerewith
10.53Securities Purchase Agreement, dated September 16, 2024, between the Company and the purchasers party thereto.8-K10.2September 18, 2024001-37746
10.54Form of Warrant Inducement Agreement, by and between the Company and each Holder8-K10.1December 12, 2024001-37746
10.55Form of Placement Agency Agreement, dated April 3, 2025, between the Company and Roth Capital Partners.8-K10.1April 4, 2025001-37746
10.56Form of Securities Purchase Agreement, dated April 3, 2025, between the Company and the purchasers party thereto.8-K10.2April 4, 2025001-37746
10.57Form of Placement Agency Agreement, dated April 21, 2025, between the Company and Roth Capital Partners.8-K10.1April 22, 2025001-37746
10.58Form of Securities Purchase Agreement, dated April 21, 2025, between the Company and the purchasers party thereto.8-K10.2April 22, 2025001-37746
10.59Standby Equity Purchase Agreement, dated June16, 2025, by and between Aptevo Therapeutics Inc. and YA II PN, LTD.8-K10.1June 17, 2025001-37746
10.60Placement Agency Agreement, dated June 18, 2025, between the Company and Roth Capital Partners.8-K10.1June 20, 2025001-37746
10.61Securities Purchase Agreement, dated June 18, 2025, between the Company and the purchasers party thereto.8-K10.2June 20, 2025001-37746
10.62Standby Equity Purchase Agreement, dated January 8, 2026 by and between Aptevo Therapeutics Inc. and YA II PN, LTD.8-K10.1January 9, 2026001-37746
16.1Letter of Baker Tilly US, LLP to the Securities and Exchange Commission dated June 23, 20258-K16.1June 23, 2025001-37746
19.1Insider trading policies and proceduresX
21.1Subsidiaries of Aptevo Therapeutics Inc.X
23.1Consent of Independent Registered Public Accounting Firm.X
31.1Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
31.2Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
ExhibitNumberDescriptionFormExhibitFiling DateFile No.FiledHerewith
32.1* · Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. · X
32.2* · Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. · X
97Compensation Recovery Policy10-K97March 5, 2024001-37746
101.INSInline XBRL Instance DocumentX
101.SCHInline XBRL Taxonomy Extension Schema With Embedded Linkbase DocumentsX
104Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)X
  • Document has been furnished, is not deemed filed and is not to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in any such filing.

† Confidential treatment granted from the Securities and Exchange Commission as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.

C Management contract or compensatory plan.

  • Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Aptevo will furnish copies of any such schedules to the Securities and Exchange Commission upon request.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.